Patents by Inventor Martin D. Meglasson

Martin D. Meglasson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11786687
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: October 17, 2023
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20210260327
    Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 26, 2021
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 10918819
    Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: February 16, 2021
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20200171259
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Application
    Filed: February 10, 2020
    Publication date: June 4, 2020
    Applicant: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 10556082
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: February 11, 2020
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 10130783
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: November 20, 2018
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20180104432
    Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
    Type: Application
    Filed: October 23, 2017
    Publication date: April 19, 2018
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 9795756
    Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: October 24, 2017
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20170128690
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 11, 2017
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 9562113
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: February 7, 2017
    Assignee: Bellerophon BCM LLC
    Inventors: Fuqiang Ruan, Thomas L. Deckwerth, Martin D. Meglasson
  • Patent number: 9550039
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: January 24, 2017
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20160115252
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Application
    Filed: January 6, 2016
    Publication date: April 28, 2016
    Inventors: Fuqiang Ruan, Thomas L. Deckwerth, Martin D. Meglasson
  • Patent number: 9260399
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: February 16, 2016
    Assignee: Bellerophon BCM LLC
    Inventors: Fuqiang Ruan, Thomas L. Deckwerth, Martin D. Meglasson
  • Publication number: 20150238720
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Application
    Filed: May 7, 2015
    Publication date: August 27, 2015
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 9032959
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: May 19, 2015
    Assignee: INO Therapeutics LLC
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20150133645
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 14, 2015
    Inventors: Fuqiang Ruan, Thomas L. Deckwerth, Martin D. Meglasson
  • Patent number: 8974766
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: March 10, 2015
    Assignee: Bellerophon BCM LLC
    Inventors: Fuqiang Ruan, Thomas L. Deckwerth, Martin D. Meglasson
  • Publication number: 20140299129
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 9, 2014
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Patent number: 8770199
    Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: July 8, 2014
    Assignee: INO Therapeutics LLC
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
  • Publication number: 20140166009
    Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.
    Type: Application
    Filed: December 4, 2013
    Publication date: June 19, 2014
    Applicant: INO Therapeutics LLC
    Inventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah